Keyword: Aurobindo Pharma
The White House asked the FDA to clear Avigan for COVID-19. FTC delays forced Aurobindo and Novartis to end generics deal. China's API output dropped.
China is repurposing existing drugs for coronavirus. South Korea arrested a Sanofi exec for a vaccine case. Novartis outlined ambitious China plan.
Aurobindo Pharma reported that the FDA has more concerns following an inspection of a solids formulation plant in India.
Rising Pharmaceuticals pleads to price fixing, and a pilot-scale lyophilization facility is being made available for pilot projects.
Catalent has been picked to manufacture BeiGene's immuno-oncology drug.
Amgen pays $2.7 billion for a 20.5% stake in BeiGene. AstraZeneca tightens its ties to China as China approves a controversial Alzheimer's drug.
In eyeing Novartis' deal to sell assets to Aurobindo, the Federal Trade Commission is reportedly delving into a lawsuit the generics maker faces.
India’s Aurobindo, which has yet to close its $1 billion deal to buy 300 Sandoz products in the U.S., continues to rack up FDA issues.
FTC review delays Sandoz-Aurobindo generics deal. Manufacturing questions push back Zolgensma decision in Japan. AZ expects mid-teens China growth.